Montanide Isa 51
Solid Tumor
Huashan HospitalActive
D
26/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 59/ 100
Competitive context
479 Active assets in the Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Mirati Therapeutics Inc. | Phase 4 | BB |
(+)-VINCRISTINE Pfizer | Phase 4 | B |
Atezolizumab Hoffmann-La Roche | Phase 2/3 | B |
Rivoceranib Beidahuang Industry Group General Hospital | Phase 3 | B |
Durvalumab GlaxoSmithKline | Phase 4 | B |
View all 50 →
Same molecule, other indications
Montanide Isa 51 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →